SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Anthera Pharmaceuticals, Inc. (ANTH)

ANTH RSS Feed
Add ANTH Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 9/5/2017 5:14:43 PM - Followers: 62 - Board type: Free - Posts Today: 0


 


 Anthera Pharmaceuticals Inc.     


                                              Nasdaq: ANTH


 

Anthera Pharmaceuticals is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company has two product candidates in development.

 

Sollpura is Anthera’s novel biotechnology-derived pancreatic enzyme replacement therapy for the potential treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.

Blisibimod is Anthera’s BAFF inhibitor for the potential treatment of systemic lupus erythematosus and IgA nephropathy.


Pipeline



                            Contact Info                                                                           
                                                                           

Anthera Pharmaceuticals, Inc. 

25801 Industrial Blvd, Suite B • Hayward, CA 94545



Press Contact: pr@anthera.com


Business Development: bd@anthera.com


 Vendors: ap@anthera.com


 Website: www.anthera.com

 

------>>Latest Developments<<-----

December 06, 2016

J. Craig Thompson promoted to Chief Executive Officer and appointed to the Board of Directors Paul F. Truex appointed as Executive Chairman of the Board Dr. Christopher Henney stepped down as Chairman ...

1
 
         
___________________________________________________________________________________________________________________________________________
Outstanding Share Data
October 31 ,2016,the Company had 41,955,126 common shares issued and outstanding
July 31,2016 the Company had 41,427,352 common shares issued and outstanding
April 27,2016 the Company had 40,987,145 common shares issued and outstanding
February 29,2016 the Company had 40,004,037 common shares issued and outstanding
November 1,2015 the Company had 39,875,405 common shares issued and outstanding
August 1,2015 the Company had 39,703,998 common shares issued and outstanding
May 1,2015 the Company had 35,816,364 common shares issued and outstanding
February 28,2015 the Company had 29,091,773 common shares issued and outstanding
November 10,2014 the Company had 22,939,553 common shares issued and outstanding
____________________________________________________________________________________________________________________________________________

MAJOR HOLDERS

 

68% of the outstanding owned by these longs

Outstanding 42mil minus Major ownership of 28.5mil = 13.5mil free trading float


28.5mil Major Holders in this,15mil Institutions,7.5mil Direct Holders,6mil Mutual Funds= 68% of 42mil os 


http://www.barrons.com/quote/stock/us/xnas/anth?mod=DNH_S

________________________________________________________________


http://finance.yahoo.com/q?s=ANTH

   Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation,

including cardiovascular and autoimmune diseases. We currently have a Phase 2 clinical program, blisibimod.It was just recently approved by FDA to move into

PHASE 3

 

   Blisibimod targets elevated levels of B-cell activating factor (BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren's Syndrome, Graves' Disease and others.


  It has taken the lupus research community over 50 years to produce a new therapy. Although it is now a year old, Benlysta (belimumab),

now marketed by GlaxoSmithKline and Human Genome Sciences, is the first human monoclonal antibody for the treatment

of lupus.




  Benlysta had a slow take-off grossing $59.2 million in sales in the last three quarters of 2011, but it was approved in numerous

countries by year's end.
Estimated sales for Benlysta in 2012 are said to be about $230 million, with first annual profits likely by 2015.


  The surprisingly slow uptake of Benlysta allows for blisibimod to develop into a promising drug as

it currently has more desirable features than that of Benlysta.


Blisibimod has a dosing regimen of one injection weekly, compared to that of Benlysta which requires a

series of dosing before the maintenance dose begins. Also, Benlysta has limitations on usage pertaining to

specific patient populations and has not been studied in combination with other biologics.

These attributes of blisibimod including a different mechanism of action, will set it apart from

Benlysta, Global Data concludes.

 

 

SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
ANTH
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ANTH News: Statement of Changes in Beneficial Ownership (4) 09/07/2017 06:57:45 PM
ANTH News: Amended Statement of Changes in Beneficial Ownership (4/a) 09/07/2017 06:57:14 PM
ANTH News: Statement of Changes in Beneficial Ownership (4) 09/07/2017 02:45:08 PM
ANTH News: Anthera Pharmaceuticals Surpasses 50% Milestone for Screening of Patients in RESULT Phase 3 Clinical Study of Sollpura in Cys... 09/07/2017 08:30:00 AM
ANTH News: Anthera Pharmaceuticals to Present at Rodman & Renshaw’s 18th Annual Global Investment Conference 09/06/2017 08:30:00 AM
PostSubject
#2109   https://seekingalpha.com/article/4104087-anthera-looks-redeem-failures Inoviorulez 09/05/17 05:14:43 PM
#2108   Nice reversal in the making off of a Klinsmann 08/30/17 02:15:28 PM
#2107   Good news - looks like settled around 1,40. Klinsmann 08/14/17 01:08:33 PM
#2106   Lots of talk that this one will bankrupt. PPHMSPHINCTER 07/11/17 06:09:12 PM
#2105   ANTH closed at highs of the day,volume was novicetrader 06/13/17 10:13:09 PM
#2104   $ANTH 1.86 spiking here. Mark 06/13/17 11:01:07 AM
#2103   What's your take on current cash position? stockweiser 06/02/17 07:50:31 PM
#2102   EOY success will change what we see today. PirateGary 05/25/17 02:29:38 PM
#2101   ANTH's reverse split repriced the warrants to about agamemnus 05/25/17 09:29:31 AM
#2100   If you liked it under $3.20, I guess agamemnus 05/25/17 09:28:30 AM
#2099   Just checking wow, hope the bleeding stops, goes PirateGary 05/19/17 12:47:00 PM
#2098   Sorry to go, Please remove me as a PirateGary 05/18/17 09:16:41 AM
#2097   It went under 2 ah, and I suspect ksuave 05/16/17 08:48:12 PM
#2096   I'm out, sold today to back a CBD PirateGary 05/16/17 07:25:38 PM
#2095   I got caught holding a bag of this ksuave 05/16/17 11:04:35 AM
#2094   No matter the opinion of Zacks, I like PirateGary 05/14/17 11:58:24 AM
#2093   What's it going to Take? PirateGary 05/12/17 05:35:48 PM
#2092   Any wisdom from the peanut gallery? PirateGary 05/12/17 08:11:05 AM
#2091   Quiet around here, any words of, well any PirateGary 05/10/17 08:32:11 PM
#2090   Acting nearly as expected after rs imo. Went Klinsmann 05/09/17 12:28:32 PM
#2089   I'm not impressed with the RS results one PirateGary 05/09/17 08:21:56 AM
#2088   $ANTH 2.26 moving Mark 05/05/17 11:39:56 AM
#2087   $ANTH 2.19 pig trying to move, 10M O/S Mark 05/05/17 11:24:13 AM
#2086   I bought on the chance Theres more to PirateGary 05/05/17 09:13:23 AM
#2085   correction "cat this quarter" not cat this month TRACING 05/05/17 02:59:36 AM
#2084   Wow, I cant believe this got by EVERYONE TRACING 05/05/17 02:40:36 AM
#2083   Agree, holding a nice position here. Hope the Mark 05/02/17 12:26:50 PM
#2082   It´s not OTC - most companies try to Klinsmann 05/02/17 12:21:19 PM
#2080   $ANTH, 2.36 only 10M O/S post split now: Mark 05/01/17 06:26:03 PM
#2079   That equals 2,64 after the split. I expect Klinsmann 05/01/17 09:06:58 AM
#2078   ANTH News: Anthera Pharmaceuticals Announces 1-for-8 Reverse Split [SMART MONEY] 05/01/17 08:51:37 AM
#2077   Anth which way do we go, anyone left? PirateGary 05/01/17 08:06:23 AM
#2076   16:01 ANTH Anthera Pharma files a Certificate of Amendment to Atlanta1 04/28/17 04:23:13 PM
#2075   1:8 split I dont like it. Now what PirateGary 04/28/17 04:21:57 PM
#2074   ANTH Reverse Split voting? l2 hunter 04/28/17 01:57:49 PM
#2073   Dilution. And reverse split spooks people. ksuave 04/28/17 01:42:16 PM
#2072   What News, the 8-K? Really droping off for PirateGary 04/28/17 01:30:07 PM
#2071   Dang, they just did. I'm out righlife 04/28/17 09:39:22 AM
#2070   I wish the company would release something, anything PirateGary 04/28/17 09:37:29 AM
#2069   Bought in, go ANTH $$ righlife 04/27/17 11:57:06 AM
#2068   Quiet in here nothing happening? PirateGary 04/21/17 01:37:34 PM
#2067   Nice additional news for ANTH today. Bottom in Klinsmann 04/10/17 11:28:47 AM
#2066   awesome ... I pulled my big order but duder54 04/07/17 11:42:38 AM
#2065   I added this morning. ksuave 04/07/17 11:36:49 AM
#2064   looking forward to the reversal. Lets see what duder54 04/07/17 11:30:39 AM
#2063   Positive results means a lot to a biotech Klinsmann 04/07/17 11:19:38 AM
#2062   I think of it as a hissy fit duder54 04/07/17 11:06:40 AM
#2061   To you as well! 0,50 test gonna happen imo Klinsmann 04/07/17 10:47:50 AM
#2060   This area I think is safe. but the duder54 04/07/17 10:44:38 AM
#2059   0,37/0,38 looks like a smart and safe entry Klinsmann 04/07/17 10:36:27 AM
PostSubject